Cargando…

Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis

AIMS: Heart failure is an increasingly recognized later stage manifestation of arrhythmogenic right ventricular cardiomyopathy (ARVC) that can require heart transplantation (HT) to appropriately treat. We aimed to study contemporary ARVC HT outcomes in a national registry. METHODS AND RESULTS: The U...

Descripción completa

Detalles Bibliográficos
Autores principales: Giuliano, Katherine, Scheel, Paul, Etchill, Eric, Fraser, Charles D., Suarez‐Pierre, Alejandro, Hsu, Steven, Wittstein, Ilan S., Kasper, Edward K., Florido, Roberta, Tandri, Harikrishna, Calkins, Hugh, Choi, Chun W., Sharma, Kavita, Kilic, Ahmet, Gilotra, Nisha A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934952/
https://www.ncbi.nlm.nih.gov/pubmed/35132806
http://dx.doi.org/10.1002/ehf2.13687
_version_ 1784671940821123072
author Giuliano, Katherine
Scheel, Paul
Etchill, Eric
Fraser, Charles D.
Suarez‐Pierre, Alejandro
Hsu, Steven
Wittstein, Ilan S.
Kasper, Edward K.
Florido, Roberta
Tandri, Harikrishna
Calkins, Hugh
Choi, Chun W.
Sharma, Kavita
Kilic, Ahmet
Gilotra, Nisha A.
author_facet Giuliano, Katherine
Scheel, Paul
Etchill, Eric
Fraser, Charles D.
Suarez‐Pierre, Alejandro
Hsu, Steven
Wittstein, Ilan S.
Kasper, Edward K.
Florido, Roberta
Tandri, Harikrishna
Calkins, Hugh
Choi, Chun W.
Sharma, Kavita
Kilic, Ahmet
Gilotra, Nisha A.
author_sort Giuliano, Katherine
collection PubMed
description AIMS: Heart failure is an increasingly recognized later stage manifestation of arrhythmogenic right ventricular cardiomyopathy (ARVC) that can require heart transplantation (HT) to appropriately treat. We aimed to study contemporary ARVC HT outcomes in a national registry. METHODS AND RESULTS: The United Network for Organ Sharing registry was queried for HT recipients from 1/1994 through 2/2020. ARVC patients were compared with non‐ARVC dilated, restrictive, and hypertrophic cardiomyopathy HT patients (HT for ischaemic and valvular disease was excluded from analysis). Post‐HT survival was assessed using Kaplan–Meier estimates. A total of 189 of 252 (75%) waitlisted ARVC patients (median age 48 years, 65% male) underwent HT, representing 0.3% of the total 65 559 HT during the study time period. Annual frequency of HT for ARVC increased significantly over time. ARVC patients had less diabetes (5% vs. 17%, P < 0.001), less cigarette use (15% vs. 23%, P < 0.001), lower pulmonary artery and pulmonary capillary wedge pressures, and lower cardiac output than the 33 659 non‐ARVC patients (P < 0.001). Ventricular assist device use was significantly lower in ARVC patients (8% vs. 32%, P < 0.001); 1 and 5 year post‐HT survival was 97% and 93% for ARVC vs. 95% and 82% for non‐ARVC HT recipients (P < 0.001). On adjusted multivariable Cox regression, ARVC had decreased risk of post‐HT death compared with non‐ARVC aetiologies (hazard ratio 0.48, 95% confidence interval 0.28–0.82, P = 0.008). Patients with ARVC also had lower risk of death or graft failure than non‐ARVC patients (hazard ratio 0.51, 95% confidence interval 0.32–0.81, P = 0.004). CONCLUSIONS: In the largest series of HT in ARVC, we found that HT is increasingly performed in ARVC, with higher survival compared with other cardiomyopathy aetiologies. The right ventricular predominant pathophysiology may require unique considerations for heart failure management, including HT.
format Online
Article
Text
id pubmed-8934952
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89349522022-03-24 Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis Giuliano, Katherine Scheel, Paul Etchill, Eric Fraser, Charles D. Suarez‐Pierre, Alejandro Hsu, Steven Wittstein, Ilan S. Kasper, Edward K. Florido, Roberta Tandri, Harikrishna Calkins, Hugh Choi, Chun W. Sharma, Kavita Kilic, Ahmet Gilotra, Nisha A. ESC Heart Fail Original Articles AIMS: Heart failure is an increasingly recognized later stage manifestation of arrhythmogenic right ventricular cardiomyopathy (ARVC) that can require heart transplantation (HT) to appropriately treat. We aimed to study contemporary ARVC HT outcomes in a national registry. METHODS AND RESULTS: The United Network for Organ Sharing registry was queried for HT recipients from 1/1994 through 2/2020. ARVC patients were compared with non‐ARVC dilated, restrictive, and hypertrophic cardiomyopathy HT patients (HT for ischaemic and valvular disease was excluded from analysis). Post‐HT survival was assessed using Kaplan–Meier estimates. A total of 189 of 252 (75%) waitlisted ARVC patients (median age 48 years, 65% male) underwent HT, representing 0.3% of the total 65 559 HT during the study time period. Annual frequency of HT for ARVC increased significantly over time. ARVC patients had less diabetes (5% vs. 17%, P < 0.001), less cigarette use (15% vs. 23%, P < 0.001), lower pulmonary artery and pulmonary capillary wedge pressures, and lower cardiac output than the 33 659 non‐ARVC patients (P < 0.001). Ventricular assist device use was significantly lower in ARVC patients (8% vs. 32%, P < 0.001); 1 and 5 year post‐HT survival was 97% and 93% for ARVC vs. 95% and 82% for non‐ARVC HT recipients (P < 0.001). On adjusted multivariable Cox regression, ARVC had decreased risk of post‐HT death compared with non‐ARVC aetiologies (hazard ratio 0.48, 95% confidence interval 0.28–0.82, P = 0.008). Patients with ARVC also had lower risk of death or graft failure than non‐ARVC patients (hazard ratio 0.51, 95% confidence interval 0.32–0.81, P = 0.004). CONCLUSIONS: In the largest series of HT in ARVC, we found that HT is increasingly performed in ARVC, with higher survival compared with other cardiomyopathy aetiologies. The right ventricular predominant pathophysiology may require unique considerations for heart failure management, including HT. John Wiley and Sons Inc. 2022-02-08 /pmc/articles/PMC8934952/ /pubmed/35132806 http://dx.doi.org/10.1002/ehf2.13687 Text en © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Giuliano, Katherine
Scheel, Paul
Etchill, Eric
Fraser, Charles D.
Suarez‐Pierre, Alejandro
Hsu, Steven
Wittstein, Ilan S.
Kasper, Edward K.
Florido, Roberta
Tandri, Harikrishna
Calkins, Hugh
Choi, Chun W.
Sharma, Kavita
Kilic, Ahmet
Gilotra, Nisha A.
Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis
title Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis
title_full Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis
title_fullStr Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis
title_full_unstemmed Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis
title_short Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis
title_sort heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934952/
https://www.ncbi.nlm.nih.gov/pubmed/35132806
http://dx.doi.org/10.1002/ehf2.13687
work_keys_str_mv AT giulianokatherine hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis
AT scheelpaul hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis
AT etchilleric hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis
AT frasercharlesd hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis
AT suarezpierrealejandro hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis
AT hsusteven hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis
AT wittsteinilans hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis
AT kasperedwardk hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis
AT floridoroberta hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis
AT tandriharikrishna hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis
AT calkinshugh hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis
AT choichunw hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis
AT sharmakavita hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis
AT kilicahmet hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis
AT gilotranishaa hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis